103 related articles for article (PubMed ID: 35436147)
1. Sociodemographic and Facility-Related Disparities in the Delivery of Guideline-Concordant Therapy Among Patients With Esophageal Adenocarcinoma.
da Costa WL; Camp ER; Thrift AP
JCO Oncol Pract; 2022 Jul; 18(7):e1181-e1197. PubMed ID: 35436147
[TBL] [Abstract][Full Text] [Related]
2. Staging Concordance and Guideline-Concordant Treatment for Esophageal Adenocarcinoma.
da Costa WL; Gu X; Farjah F; Groth SS; Burt BM; Ripley RT; Carrott PW; Massarweh NN
Ann Thorac Surg; 2022 Jan; 113(1):279-285. PubMed ID: 33484675
[TBL] [Abstract][Full Text] [Related]
3. Patient- and system-level factors associated with racial/ethnic disparities in the delivery of guideline-concordant therapy among US patients with gastric cancer.
da Costa WL; Tan MC; Camp ER; Thrift AP
J Surg Oncol; 2024 May; ():. PubMed ID: 38752435
[TBL] [Abstract][Full Text] [Related]
4. Hospital Volume Predicts Guideline-Concordant Care in Stage III Esophageal Cancer.
Adhia AH; Feinglass JM; Schlick CJR; Merkow RP; Bilimoria KY; Odell DD
Ann Thorac Surg; 2022 Oct; 114(4):1176-1182. PubMed ID: 34481801
[TBL] [Abstract][Full Text] [Related]
5. Disparities in Stage-Specific Guideline-Concordant Cancer-Directed Treatment for Patients with Pancreatic Adenocarcinoma.
Hamad A; DePuccio M; Reames BN; Dave A; Kurien N; Cloyd JM; Shen C; Pawlik TM; Tsung A; McAlearney AS; Ejaz A
J Gastrointest Surg; 2021 Nov; 25(11):2889-2901. PubMed ID: 33768427
[TBL] [Abstract][Full Text] [Related]
6. Clinical Understaging, Treatment Response, and Survival Among Esophageal Adenocarcinoma Patients.
da Costa WL; Gu X; Farjah F; Groth SS; Burt BM; Ripley RT; Massarweh NN
J Surg Res; 2022 Nov; 279():256-264. PubMed ID: 35797753
[TBL] [Abstract][Full Text] [Related]
7. Esophageal Cancer Presentation, Treatment, and Outcomes Vary With Hospital Safety-Net Burden.
Sridhar P; Bhatt M; Qureshi MM; Asokan S; Truong MT; Suzuki K; Mak KS; Litle VR
Ann Thorac Surg; 2019 May; 107(5):1472-1479. PubMed ID: 30605641
[TBL] [Abstract][Full Text] [Related]
8. Clinical-Pathologic Correlation and Guideline Concordance in Resectable Non-Small Cell Lung Cancer.
Stokes SM; Massarweh NN; Stringham JR; Varghese TK
Ann Thorac Surg; 2019 Sep; 108(3):837-844. PubMed ID: 31026431
[TBL] [Abstract][Full Text] [Related]
9. Utilization of surgery in trimodality-eligible patients with locally advanced esophageal adenocarcinoma in a nonprotocol setting.
Murphy CC; Hofstetter WL; Correa AM; Ajani JA; Komaki RU; Swisher SG
Dis Esophagus; 2013; 26(7):708-15. PubMed ID: 23350713
[TBL] [Abstract][Full Text] [Related]
10. Influence of race, insurance, socioeconomic status, and hospital type on receipt of guideline-concordant adjuvant systemic therapy for locoregional breast cancers.
Wu XC; Lund MJ; Kimmick GG; Richardson LC; Sabatino SA; Chen VW; Fleming ST; Morris CR; Huang B; Trentham-Dietz A; Lipscomb J
J Clin Oncol; 2012 Jan; 30(2):142-50. PubMed ID: 22147735
[TBL] [Abstract][Full Text] [Related]
11. Nonadherence to Multimodality Cancer Treatment Guidelines in the United States.
Tchelebi LT; Shen B; Wang M; Potters L; Herman J; Boffa D; Segel JE; Park HS; Zaorsky NG
Adv Radiat Oncol; 2022; 7(5):100938. PubMed ID: 35469182
[TBL] [Abstract][Full Text] [Related]
12. Treatment utilization and outcomes in elderly patients with locally advanced esophageal carcinoma: a review of the National Cancer Database.
Vlacich G; Samson PP; Perkins SM; Roach MC; Parikh PJ; Bradley JD; Lockhart AC; Puri V; Meyers BF; Kozower B; Robinson CG
Cancer Med; 2017 Dec; 6(12):2886-2896. PubMed ID: 29139215
[TBL] [Abstract][Full Text] [Related]
13. Variation in Diagnosis, Treatment, and Outcome of Esophageal Cancer in a Regionalized Care System in Ontario, Canada.
Habbous S; Yermakhanova O; Forster K; Holloway CMB; Darling G
JAMA Netw Open; 2021 Sep; 4(9):e2126090. PubMed ID: 34546371
[TBL] [Abstract][Full Text] [Related]
14. Integrated cancer networks improve compliance with national guidelines and outcomes for resectable gastric cancer.
Thiels CA; Hanson KT; Habermann EB; Boughey JC; Grotz TE
Cancer; 2020 Mar; 126(6):1283-1294. PubMed ID: 31821545
[TBL] [Abstract][Full Text] [Related]
15. Use of multimodality neoadjuvant therapy for esophageal cancer in the United States: assessment of 987 hospitals.
Merkow RP; Bilimoria KY; McCarter MD; Chow WB; Ko CY; Bentrem DJ
Ann Surg Oncol; 2012 Feb; 19(2):357-64. PubMed ID: 21769460
[TBL] [Abstract][Full Text] [Related]
16. Evaluating disparities in delivery of neoadjuvant guideline-based chemoradiation for rectal cancer: A multicenter, propensity score-weighted cohort study.
Lau LW; Kethman WC; Bingmer KE; Ofshteyn A; Steinhagen E; Charles R; Dietz D; Stein SL
J Surg Oncol; 2021 Oct; 124(5):810-817. PubMed ID: 34159619
[TBL] [Abstract][Full Text] [Related]
17. Population-Based Study on Cancer Subtypes, Guideline-Concordant Adjuvant Therapy, and Survival Among Women With Stage I-III Breast Cancer.
Hsieh MC; Zhang L; Wu XC; Davidson MB; Loch M; Chen VW
J Natl Compr Canc Netw; 2019 Jun; 17(6):676-686. PubMed ID: 31200362
[TBL] [Abstract][Full Text] [Related]
18. Patterns of computed tomography surveillance in survivors of colorectal cancer at Veterans Health Administration facilities.
Sehdev A; Sherer EA; Hui SL; Wu J; Haggstrom DA
Cancer; 2017 Jun; 123(12):2338-2351. PubMed ID: 28211937
[TBL] [Abstract][Full Text] [Related]
19. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer.
Speicher PJ; Ganapathi AM; Englum BR; Hartwig MG; Onaitis MW; D'Amico TA; Berry MF
J Thorac Oncol; 2014 Aug; 9(8):1195-201. PubMed ID: 25157773
[TBL] [Abstract][Full Text] [Related]
20. Disparities in guideline-concordant treatment for node-positive, non-small cell lung cancer following surgery.
Farrow NE; An SJ; Speicher PJ; Harpole DH; D'Amico TA; Klapper JA; Hartwig MG; Tong BC
J Thorac Cardiovasc Surg; 2020 Jul; 160(1):261-271.e1. PubMed ID: 31924363
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
